Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVVD NASDAQ:MRVI NASDAQ:RZLT NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVVDInvivyd$1.26-1.6%$0.84$0.35▼$2.74$151.38M0.557.91 million shs1.82 million shsMRVIMaravai LifeSciences$2.89+6.3%$2.49$1.66▼$9.50$738.00M0.292.27 million shs1.12 million shsRZLTRezolute$7.72+3.3%$6.41$2.21▼$8.34$671.61M0.03923,841 shs1.33 million shsTYRATyra Biosciences$12.36+0.4%$11.24$6.42▼$29.60$658.79M1.09296,691 shs173,104 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVVDInvivyd-10.49%+10.34%+81.02%+76.11%+11.30%MRVIMaravai LifeSciences+1.87%+11.48%+4.21%+30.14%-67.58%RZLTRezolute-2.86%-6.04%+14.92%+80.87%+42.29%TYRATyra Biosciences-1.68%+1.48%+14.73%+28.36%-42.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVVDInvivyd$1.26-1.6%$0.84$0.35▼$2.74$151.38M0.557.91 million shs1.82 million shsMRVIMaravai LifeSciences$2.89+6.3%$2.49$1.66▼$9.50$738.00M0.292.27 million shs1.12 million shsRZLTRezolute$7.72+3.3%$6.41$2.21▼$8.34$671.61M0.03923,841 shs1.33 million shsTYRATyra Biosciences$12.36+0.4%$11.24$6.42▼$29.60$658.79M1.09296,691 shs173,104 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVVDInvivyd-10.49%+10.34%+81.02%+76.11%+11.30%MRVIMaravai LifeSciences+1.87%+11.48%+4.21%+30.14%-67.58%RZLTRezolute-2.86%-6.04%+14.92%+80.87%+42.29%TYRATyra Biosciences-1.68%+1.48%+14.73%+28.36%-42.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVVDInvivyd 3.25Buy$3.18152.65% UpsideMRVIMaravai LifeSciences 2.18Hold$5.2280.58% UpsideRZLTRezolute 3.20Buy$11.6751.12% UpsideTYRATyra Biosciences 3.14Buy$31.86157.74% UpsideCurrent Analyst Ratings BreakdownLatest IVVD, MRVI, RZLT, and TYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025TYRATyra BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$36.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.009/2/2025TYRATyra BiosciencesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$35.008/27/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/25/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $1.008/22/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/15/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $3.008/12/2025MRVIMaravai LifeSciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$7.00 ➝ $5.007/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.006/26/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVVDInvivyd$25.38M5.96N/AN/A$0.56 per share2.25MRVIMaravai LifeSciences$219.83M3.36$0.67 per share4.32$2.28 per share1.27RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVVDInvivyd-$169.93M-$0.92N/A11.45N/A-238.33%-177.89%-90.96%11/13/2025 (Estimated)MRVIMaravai LifeSciences-$144.85M-$1.36N/AN/AN/A-90.03%-17.60%-9.30%11/6/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.78N/AN/AN/AN/A-31.22%-29.49%11/6/2025 (Estimated)Latest IVVD, MRVI, RZLT, and TYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/14/2025Q2 2025IVVDInvivyd-$0.04-$0.12-$0.08-$0.12$23.16 million$11.79 million8/14/2025Q2 2025TYRATyra Biosciences-$0.53-$0.47+$0.06-$0.47N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIVVDInvivydN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVVDInvivydN/A1.331.33MRVIMaravai LifeSciences0.685.164.49RZLTRezoluteN/A8.438.43TYRATyra BiosciencesN/A21.9421.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVVDInvivyd70.36%MRVIMaravai LifeSciences50.25%RZLTRezolute82.97%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipIVVDInvivyd25.40%MRVIMaravai LifeSciences2.11%RZLTRezolute18.39%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVVDInvivyd100120.14 million89.63 millionOptionableMRVIMaravai LifeSciences610255.36 million249.97 millionOptionableRZLTRezolute4087.00 million71.00 millionOptionableTYRATyra Biosciences2053.30 million45.20 millionOptionableIVVD, MRVI, RZLT, and TYRA HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from BrokeragesSeptember 15 at 2:44 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Upgraded by Wall Street Zen to "Hold" RatingSeptember 15 at 2:13 AM | marketbeat.comWall Street Zen Upgrades Tyra Biosciences (NASDAQ:TYRA) to HoldSeptember 14 at 3:47 AM | americanbankingnews.comTyra Biosciences, Inc. $TYRA Shares Acquired by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comTyra Biosciences price target raised to $36 from $30 at OppenheimerSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Has $1.31 Million Stock Holdings in Tyra Biosciences, Inc. $TYRASeptember 9, 2025 | marketbeat.comNMIBC Pipeline Outlook 2025: Insights Into Therapies, Research, and Market PotentialSeptember 8, 2025 | theglobeandmail.comNuveen LLC Acquires New Stake in Tyra Biosciences, Inc. $TYRASeptember 7, 2025 | marketbeat.comWe're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash WiselySeptember 6, 2025 | finance.yahoo.comTyra Biosciences, Inc. $TYRA Shares Sold by Ally Bridge Group NY LLCSeptember 5, 2025 | marketbeat.comTyra Biosciences, Inc. $TYRA Shares Purchased by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comRaymond James Initiates Coverage of Tyra Biosciences (TYRA) with Strong Buy RecommendationSeptember 4, 2025 | msn.comTyra Biosciences management to meet with OppenheimerSeptember 4, 2025 | msn.comTyra Biosciences initiated with a Strong Buy at Raymond JamesSeptember 3, 2025 | msn.comWalleye Capital LLC Has $1.31 Million Stake in Tyra Biosciences, Inc. $TYRASeptember 1, 2025 | marketbeat.comAlphaQuest LLC Raises Stock Holdings in Tyra Biosciences, Inc. $TYRAAugust 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comTyra Biosciences initiates paediatric study for achondroplasia treatmentAugust 22, 2025 | finance.yahoo.comTyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric AchondroplasiaAugust 21, 2025 | prnewswire.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Buy" from AnalystsAugust 21, 2025 | marketbeat.comTyra Biosciences Announces Participation at Upcoming Investor EventsAugust 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVVD, MRVI, RZLT, and TYRA Company DescriptionsInvivyd NASDAQ:IVVD$1.26 -0.02 (-1.56%) Closing price 04:00 PM EasternExtended Trading$1.26 +0.00 (+0.40%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Maravai LifeSciences NASDAQ:MRVI$2.89 +0.17 (+6.25%) Closing price 04:00 PM EasternExtended Trading$2.86 -0.03 (-1.04%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Rezolute NASDAQ:RZLT$7.72 +0.25 (+3.35%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.08 (+1.04%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Tyra Biosciences NASDAQ:TYRA$12.36 +0.05 (+0.41%) Closing price 04:00 PM EasternExtended Trading$12.36 +0.01 (+0.04%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
